Conference Track

From Podium to Practice: HIV Highlights From San Francisco

Source: CCO Independent Conference Coverage of the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Detectability of Tuberculosis Infection by T-Cell–Based Interferon Gamma Release Assay Attenuated in HIV-Infected Individuals With Low CD4+ Cell Counts
In Patients With Isolated M184V, Use of Lamivudine or Emtricitabine as Component of 2 NRTIs Plus Boosted PI Regimen Is Sufficient to Achieve Virologic Suppression
Antiretroviral Pregnancy Registry: In Utero Exposure to Tenofovir Not Associated With Increased Prevalence of Congenital Abnormalities
VICTOR-E1 Extension: Continuous Vicriviroc for Up to 2 Years Associated With Sustained Virologic and Immunologic Responses in Treatment-Experienced Patients
STARTMRK: Comparable Efficacy of First-line Raltegravir- vs Efavirenz-Based Regimens Through 96 Weeks
Immediate Antiretroviral Therapy Initiation in Patients With HIV-Associated Tuberculosis Does Not Decrease Morbidity and Mortality But Does Increase Incidence of Severe AEs
Single Intravenous Doses of PRO 140 CCR5 Inhibitor Potent, Safe, and Well Tolerated in HIV-Infected Individuals
Recombinant Human IL-7 Increases CD4+ and CD8+ T Cells in Patients Receiving Antiretroviral Therapy
BITE: Multicomponent Nutritional Supplement Dramatically Slows Immunologic Decline in HIV-Infected Individuals Not Receiving Antiretroviral Therapy
CIPRAHT001: Dramatic Reductions in Morbidity and Mortality Observed in Haiti When Antiretroviral Therapy Initiated at CD4+ Cell Counts of 200-350 cells/mm³
Peripheral Endothelial Function Significantly Decreased After Initiation of Antiretroviral Therapy
MERIT Subanalysis: Greater CD4+ Cell Count Increase With Maraviroc May Be Related to Effects on Immune Activation and Inflammation

Expert Analysis

From Podium to Practice: HIV Highlights From San Francisco

Faculty:

Judith S. Currier, MD, MSc
Joel E. Gallant, MD, MPH
Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new findings highlighting challenges associated with implementation of revised recommendations for routine, opt-out HIV screening of all patients in healthcare settings
Cite recent findings on the role of immune modulation strategies in the management of patients with HIV infection including nutritional supplementation and cytokine therapy
Recount the latest data on the safety and efficacy of CCR5-targeted agents for the treatment of HIV infection
Summarize new results concerning the optimal timing of antiretroviral treatment initiation in resource-limited settings and in the setting of opportunistic infection

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: 11/05/09

Expiration Date: 11/04/10

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.75 Nursing contact hours

Pharmacists: 0.75 contact hours (0.08 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by USF Health and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.